AMGN vs GILD
Amgen Inc. and Gilead Sciences, Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | AMGN | GILD |
|---|---|---|
| Revenue | $36.8B | $29.4B |
| Net income | $7.7B | $8.5B |
| Gross margin | 67.2% | 78.8% |
| Net margin | 21.0% | 28.9% |
| Return on equity | 106.1% | 40.5% |
| Diluted EPS | $14.23 | $6.78 |
| Dividend / share | $9.66 | $3.16 |
| Payout ratio | 66.5% | 47.0% |
| Free cash flow | $8.1B | $9.5B |
| Equity | $8.7B | $22.7B |
| Net debt / equity | 5.25× | 0.77× |
| Current ratio | 1.14× | 1.55× |
| Revenue CAGR 5y | 7.6% | 3.6% |
| Profit CAGR 5y | 1.2% | 133.3% |
AMGN bills 1.2× the revenue of GILD, and GILD keeps more of each dollar of revenue as profit (28.9% against 21.0%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | AMGN | GILD |
|---|---|---|
| FY2025 | $36.8B | $29.4B |
| FY2024 | $33.4B | $28.8B |
| FY2023 | $28.2B | $27.1B |
| FY2022 | $26.3B | $27.3B |
| FY2021 | $26.0B | $27.3B |
| FY2020 | $25.4B | $24.7B |
| FY2019 | $23.4B | $22.4B |
| FY2018 | $23.7B | $22.1B |
| FY2017 | $22.8B | $26.1B |
| FY2016 | $23.0B | $30.4B |
Bottom line
| Fiscal year | AMGN | GILD |
|---|---|---|
| FY2025 | $7.7B | $8.5B |
| FY2024 | $4.1B | $480.0M |
| FY2023 | $6.7B | $5.7B |
| FY2022 | $6.6B | $4.6B |
| FY2021 | $5.9B | $6.2B |
| FY2020 | $7.3B | $123.0M |
| FY2019 | $7.8B | $5.4B |
| FY2018 | $8.4B | $5.5B |
| FY2017 | $2.0B | $4.6B |
| FY2016 | $7.7B | $13.5B |
19 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +$7,308,000,000 | AMGN |
| FY2024 | +$4,670,000,000 | AMGN |
| FY2023 | +$1,074,000,000 | AMGN |
| FY2022 | −$958,000,000 | GILD |
| FY2021 | −$1,326,000,000 | GILD |
| FY2020 | +$735,000,000 | AMGN |
| FY2019 | +$913,000,000 | AMGN |
| FY2018 | +$1,620,000,000 | AMGN |
| FY2017 | −$3,258,000,000 | GILD |
| FY2016 | −$7,399,000,000 | GILD |
| FY2015 | −$10,977,000,000 | GILD |
| FY2014 | −$4,827,000,000 | GILD |
| FY2013 | +$7,474,000,000 | AMGN |
| FY2012 | +$7,563,000,000 | AMGN |
| FY2011 | +$7,196,615,000 | AMGN |
| FY2010 | +$7,103,580,000 | AMGN |
| FY2009 | +$7,630,617,000 | AMGN |
| FY2008 | +$9,667,250,000 | AMGN |
| FY2007 | +$10,540,955,000 | AMGN |
The higher-revenue side has changed between AMGN and GILD over this period. The gap has narrowed since the earliest year compared.
19 of 19 comparable fiscal years — a year missing data on either side is not counted.
19 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −7.9 pp | GILD |
| FY2024 | +10.6 pp | AMGN |
| FY2023 | +3.1 pp | AMGN |
| FY2022 | +8.2 pp | AMGN |
| FY2021 | −0.0 pp | GILD |
| FY2020 | +28.2 pp | AMGN |
| FY2019 | +9.7 pp | AMGN |
| FY2018 | +10.7 pp | AMGN |
| FY2017 | −9.1 pp | GILD |
| FY2016 | −10.8 pp | GILD |
| FY2015 | −23.4 pp | GILD |
| FY2014 | −22.7 pp | GILD |
| FY2013 | −0.1 pp | GILD |
| FY2012 | −1.4 pp | GILD |
| FY2011 | −9.6 pp | GILD |
| FY2010 | −5.6 pp | GILD |
| FY2009 | −6.0 pp | GILD |
| FY2008 | −9.9 pp | GILD |
| FY2007 | −16.4 pp | GILD |
The higher net margin has changed hands between AMGN and GILD over this period.
19 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
GILD's net margin has been more volatile than AMGN's over the 19 comparable fiscal years — 13.7 percentage points of standard deviation against 6.7.
19 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between AMGN and GILD over these 19 fiscal years — AMGN led in 6 and GILD in 13.
19 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
AMGN's return on equity has been more volatile than GILD's over the 19 comparable fiscal years — 38.6 percentage points of standard deviation against 25.9.
19 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between AMGN and GILD over these 19 fiscal years — AMGN led in 8 and GILD in 11.
19 of 19 comparable fiscal years — a year missing data on either side is not counted.